Detalles de la búsqueda
1.
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.
Br J Clin Pharmacol
; 81(1): 148-60, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26345283
2.
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
J Clin Oncol
; 23(11): 2534-43, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15699478
3.
Population pharmacokinetics of bevacizumab in cancer patients with external validation.
Cancer Chemother Pharmacol
; 78(2): 341-51, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27329360
4.
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
BioDrugs
; 16(1): 63-70, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-11968154
5.
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
AAPS J
; 16(5): 1056-63, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24942210
6.
Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
Cancer Chemother Pharmacol
; 71(3): 575-80, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23228985
7.
A guide to rational dosing of monoclonal antibodies.
Clin Pharmacokinet
; 51(2): 119-35, 2012 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22257150
8.
Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.
MAbs
; 2(6): 613-24, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20818176
9.
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
J Clin Oncol
; 25(6): 675-81, 2007 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17308272
10.
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
Cancer Immunol Immunother
; 55(6): 717-27, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16151804
11.
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
J Clin Oncol
; 24(26): 4324-32, 2006 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-16896006
Resultados
1 -
11
de 11
1
Próxima >
>>